NEW YORK (GenomeWeb News) – Shares of Pacific Biosciences climbed 12 percent in Friday afternoon trade after regulatory documents filed Thursday showed that Mike Hunkapiller, the firm's chairman, president, and CEO, had purchased 200,000 shares of the firm's stock on the open market.

According to a Form 4 filed with the US Securities and Exchange Commission, Hunkapiller bought the shares in multiple transactions at prices ranging from $3.51 to $3.72 and at an average price of $3.61 per share. Hunkapiller now owns 1.7 million shares of the firm's stock, according to the filing.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.

Sponsored by
Thermo Fisher Scientific

In this webinar, the first in the “New Frontiers in Liquid Biopsy Research” series, Bea Bellosillo, head of pathology at the Hospital del Mar, will discuss her experience evaluating an early-access lung cancer panel that detects copy number variants and fusions.